The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced online publication of the BLUE-C study results in The New England Journal of Medicine. The peer-reviewed study, " Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening", will also appear in the journal's March 14, 2024 print issue. The 20,000-participant BLUE-C study was designed to determine the performance characteristics of Exact Sciences’ ...